Skip to main navigation Skip to search Skip to main content

Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children

  • Swati Mummidivarpu
  • , Utkarsh J. Dang
  • , Michael Ziemba
  • , Yetrib Hathout
  • , Paula R. Clemens
  • , Jesse Damsker
  • , Laura Hagerty
  • , William J. Jusko
  • , Edward C. Smith
  • , Jean K. Mah
  • , Michela Guglieri
  • , Yoram Nevo
  • , Nancy Kuntz
  • , Craig M. McDonald
  • , Monique M. Ryan
  • , Diana Castro
  • , Richard S. Finkel
  • , Laurie S. Conklin
  • , John M. McCall
  • , Kanneboyina Nagaraju
  • John van den Anker, Eric P. Hoffman
  • State University of New York Binghamton University
  • Carleton University
  • University of Pittsburgh
  • ReveraGen BioPharma, Inc.
  • Rare Disease Research LLC
  • University of Calgary
  • Newcastle University
  • Tel Aviv University
  • Children's Memorial Hospital
  • University of California at Davis
  • University of Melbourne
  • University of Texas Southwestern Medical Center
  • Nemours Children's Clinic
  • Children's National Medical Center

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: Corticosteroid agonists of the glucocorticoid receptor are a mainstay of therapeutics for pro-inflammatory conditions. Vamorolone is a novel partial agonist that is differentiated from the other members of the corticosteroid class by non-metabolism by 11β-hydroxysteroid dehydrogenases, antagonism of the mineralocorticoid receptor, and differential co-factor binding. Our objective was to define the pharmacodynamic response of serum proteins to vamorolone. Methods: Clinical trial participants with Duchenne muscular dystrophy (4 to <7 yr; n = 39; mean [SD] age = 5.3 [1.0]) enrolled in a multiple ascending dose study of vamorolone were studied (24-fold dose range). Dose-response and exposure–response of 1,305 serum proteins were defined by intra-subject longitudinal changes (baseline vs. Day 14). Results: Dose-response analysis identified 159 of 1,305 serum proteins as dose-responsive to vamorolone (12 % of proteins tested; 20 % increased, 80 % decreased). Two inflammatory networks showed drug-responsive suppression. One centered on extracellular serine proteases and lymphotoxins (PI3, KLK7, KLK8, KLK11, lymphotoxins A, B) converging on NFκB. The second centered on cytokines (CCL22/MDC, CCL21, CCL14, CXCL12) and IL23 signaling. In the IL23 network, acutely responsive anti-inflammatory proteins included increases of an inhibitor of IL17 signaling (IL17RC) and decreases of IL23 (IL12B:IL23A). A protein associated with resistance to environmental microbes, PTP1C, showed strong induction and is a novel candidate for aspects of corticosteroid efficacy. Two networks of cell-associated proteins were identified as drug responsive that may represent muscle tissue response (efficacy): connective tissue remodeling upstream of Notch signaling, and plasma membrane proteins impinging on AKT1 signaling. Conclusion: The serum proteome pharmacodynamics of the response to vamorolone was defined.

Original languageEnglish
Article number109721
JournalSteroids
Volume225
DOIs
StatePublished - Jan 2026

Keywords

  • Glucocorticoid receptor
  • NR3C1 gene
  • Pharmacodynamics
  • Serum proteomics
  • Vamorolone

Fingerprint

Dive into the research topics of 'Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children'. Together they form a unique fingerprint.

Cite this